Endocrine Abstracts

Introduction: Disruption of the hypothalamic dopaminergic inhibitory control of prolactin (PRL) secretion results in hyperprolactinaemia. We have previously shown in a large series of patients with non-functioning pituitary macroadenomas that serum PRL virtually never exceeds 2000 mU/l in the absence of PRL elevating medications. Current data on the effect of other sellar/parasellar masses are limited.Objective: To investigate the range of PRL values at ...

Background: Pituitary stalk compression by sellar/parasellar tumours [commonly non-functioning pituitary adenomas (NFA) or craniopharyngiomas (CR)] is one of the causes of hyperprolactinaemia. However, in such cases the upper limits of serum prolactin (PRL) are not clearly defined ('grey zone': 3000-6000 mU/L) causing confusion in the differential diagnosis between disconnection hyperprolactinaemia and prolactin-secreting adenomas.Objective: To investiga...

IntroductionTestosterone replacement for hypogonadism comes in a variety of galenical forms. Side effects include prostatic enlargement and polycythaemia. Furthermore careful scrutiny for prostatic carcinoma is essential. We audited 205 male patients from one clinical centre to assess dose, frequency and complications profile and the effectiveness of biochemical and haematological monitoring. Data of this type in a group of this size has not been previously published.M...

BackgroundTransdermally absorbed alcohol-based testosterone gel has presented an alternative method of gonadal therapy. This study was designed to investigate the clinical effectiveness of this alternative hormonal replacement.Method97 men requiring testosterone replacement therapy for primary (21%) or secondary (79%) hypogonadism were recruited. The subjects underwent physical examination, psychological asse...

BackgroundThis study was designed to monitor the clinical effectiveness of transdermal replacement. Psychological well-being was assessed by questionnaire at 3, 6 and 12MethodWe recruited 97 men requiring testosterone replacement therapy for primary (21%) or secondary (79%) hypogonadism. All had a physical examination, biochemical and haematological blood sampling (Meston et al 2004) and psychological assessm...